YZi Labs announces investment in regenerative medicine company Renewal Bio

金色财经2025/11/11 13:14

Show original

Jinse Finance reported that YZi Labs has announced an investment in the regenerative medicine company Renewal Bio, marking YZi Labs' first biotechnology investment since expanding its investment scope in early 2025. Renewal Bio focuses on using its proprietary Stembroid™ platform to generate DNA-matched human cells and tissues from patients' own cells, aiming to address the global organ shortage crisis. This round of funding will accelerate the preclinical development of Stembroid-derived hematopoietic stem cells for the treatment of leukemia and immune diseases, and support the expansion of laboratory infrastructure.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

PoolX: Earn new token airdrops

Lock your assets and earn 10%+ APR

Lock now!

Trending news

Elliott Investment Management pointed out that Norwegian Cruise Line (NCLH) released a disappointing financial outlook for 2026, which shows a significant gap with the company's actual development potential.

Eli Lilly's Chief Financial Officer stated that once Orforglipron receives approval from the U.S. Food and Drug Administration (FDA), it is expected to take only about a week to complete the shipment of the drug to customers and patients.